NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Kidney Cancer Drugs Industry
http://www.reportlinker.com/p0611069/Global-Kidney-Cancer-Drugs-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_
This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on 'Kidney Cancer Drugs' provides market analytics specifically for the "Renal Cell Carcinoma" (RCC) market, owing to its predominance among the various types of kidney cancers. The market for Renal Cell Carcinoma (RCC) drugs is analyzed by the two major drug classes, which include: Multikinase Inhibitors, and Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 19 companies including many key and niche players such as AVEO Pharmaceuticals, AstraZeneca Plc, Bayer Schering Pharma AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck-Serono, Novartis AG, Pfizer, Inc., and WILEX AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Multikinase Inhibitors 4
Other RCC drug Classes (including Immunomodulators; mTOR
inhibitors; and other emerging drug classes.) 4
2. KIDNEY CANCER - FACTSHEET 5
3. MARKET OVERVIEW 6
Current Market Scenario and Outlook 6
Multikinase Inhibitors Dominate the Market 7
Presently Approved Drugs for the Treatment of Advanced Renal
Cell Carcinoma (RCC) 7
US and Europe Leads RCC Drugs Market Worldwide 7
Kidney Cancer Bodes Significant Potential for Targeted Therapies 7
Leading Kidney Cancer Drugs 8
Pfizer's Sutent Tops the RCC Drugs Market 8
Table 1: Leading Kidney Cancer Drugs Worldwide (2009): Sales
for Sutent, Nexavar, Afinitor, Avastin, and Proleukin 9
GSK's Votrient Threatens Sutent's Dominance 9
Nexavar Dominates Second Line Treatment for RCC 10
Table 2: Leading Drugs in the Second Line Treatment of RCC
(2009): Market Share Breakdown for Nexavar, Torisel,
Afinitor, Avastin, and Others (includes corresponding
Graph/Chart) 10
Torisel Leads Third Line Treatment for RCC 10
Table 3: Leading Drugs in the Third Line Treatment of RCC
(2017E): Market Share Breakdown for Afinitor, Axitinib,
Avastin, Torisel, and Others (includes corresponding
Graph/Chart) 10
4. KIDNEY CANCER: A GLIMPSE INTO THE DISEASE, CAUSES, SYMPTOMS,
AND DIAGNOSIS 11
Kidney Cancer: Disease Overview 11
Causes 11
Symptoms and Signs 11
Stages 11
Renal Cell Carcinoma (RCC): The Most Common Kidney Cancer 12
Types 12
Symptoms and Signs 12
Diagnosis 12
5. KIDNEY CANCER TREATMENT 13
Surgical Treatment 13
Targeted Therapies 14
Multi-kinase Inhibitors 14
mTOR Inhibitors 14
Oral Targeted Therapies 15
Injectable Targeted Therapy 15
Pros and Cons of Targeted Therapies 15
Monoclonal Antibodies 15
Immunomodulators 16
Aldesleukin (Proleukin®) 16
Interferon alpha-2 (Roferon-A®) 16
6. PROFILES OF MAJOR KIDNEY CANCER DRUGS 17
Sutent (Sunitinib) 17
Sutent Vs. Interferon-alpha and IFN-alpha therapies 17
Nexavar (Sorafenib) 17
Torisel (Temsirolimus) 18
Votrient (Pazopanib) 18
Avastin (Bevacizumab) 18
Afinitor (Everolimus) 18
7. PIPELINE ANALYSIS 19
Kidney Cancer Pipeline: As of 2010 19
Select Pipeline Drugs - A Review 19
Axitinib (Pfizer) 19
Tivozanib (AVEO Pharmaceuticals) 19
RENCAREX (WILEX) 20
TroVax (Oxford BioMedica) 20
8. CANCER STATISTICS 21
Cancer Incidence - Statistics on New Cases 21
Table 4: Global Cancer Incidence by Region: 2009 (includes
corresponding Graph/Chart) 21
Table 5: Global Cancer Incidence by Income Group: 2009
(includes corresponding Graph/Chart) 22
Table 6: Cancer Incidence in Upper Middle Income Countries by
Site: 2009 (includes corresponding Graph/Chart) 22
Table 7: Cancer Incidence in Lower Middle Income Countries by
Site: 2009 (includes corresponding Graph/Chart) 23
Table 8: Cancer Incidence in High Income Countries by Site:
2009 (includes corresponding Graph/Chart) 24
9. RECENT INDUSTRY ACTIVITY AND PRODUCT APPROVALS 25
WILEX Grants Exclusive US Commercialisation Rights for
RENCAREX to Prometheus 25
AVEO Collaborates with Astellas to Develop and Commercialize
Tivozanib 25
WILEX Announces End Results of REDECT Phase 3 Registration
Trial with Redectane® 25
NICE Rejects Novartis' Kidney Cancer Drug Everolimus 26
GlaxoSmithKline Gains Conditional EU Approval for Votrient
(pazopanib) 26
Prometheus and Novartis Enters into Commercialization Agreement 26
Cipla Launches Soranib Cancer Medicine 26
Roche Acquires Genentech 27
Novartis' Afinitor® Obtains EC Approval for Advanced RCC
Treatment 27
Novartis Obtains FDA Approval for Afinitor 27
Roche Receives FDA Approval for Avastin in Combination with
Interferon-Alpha for RCC Treatment 27
Pfizer's Sutent Obtains Recommendation as First Line Treatment
for mRCC 28
GlaxoSmithKline Receives FDA Approval for Votrient 28
Oxford BioMedica's TroVax Fails Kidney Cancer Clinical Trial 28
Genomic Health to Collaborate with Pfizer for New Genomic Test 28
Roche's Avastin Bags European Approval for Renal Cancer Treatment 28
Wyeth's TORISEL Receives FDA Approval 29
AstraZeneca's Novel Cancer Drug, AZD2171, Dubbed Recentin 29
10. FOCUS ON SELECT GLOBAL PLAYERS 30
AVEO Pharmaceuticals (US) 30
AstraZeneca Plc. (UK) 31
Bayer Schering Pharma AG (Germany) 31
Bristol-Myers Squibb Co. (US) 32
Onyx Pharmaceuticals, Inc. (US) 32
F. Hoffmann-La Roche Ltd. (Switzerland) 33
GlaxoSmithKline Plc. (UK) 33
Merck-Serono (Switzerland) 34
Novartis AG (Switzerland) 34
Pfizer, Inc. (US) 34
WILEX AG (Germany) 35
11. GLOBAL MARKET PERSPECTIVE 36
Table 9: World Recent Past, Current & Future Analysis for
Renal Cell Carcinoma (RCC) Drugs by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed by Annual Sales Figures in US$ Million
for Years 2008 through 2017 (includes corresponding
Graph/Chart) 36
Table 10: World 10-Year Perspective for Renal Cell Carcinoma
(RCC) Drugs by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart) 37
Table 11: World Recent Past, Current & Future Analysis for
Multikinase Inhibitors by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed by Annual Sales Figures in US$ Million
for Years 2008 through 2017 (includes corresponding
Graph/Chart) 38
Table 12: World 10-Year Perspective for Multikinase Inhibitors
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) 39
Table 13: World Recent Past, Current & Future Analysis for
Other RCC Drugs by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) 40
Table 14: World 10-Year Perspective for Other RCC Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) 41
12. THE UNITED STATES 42
A.Market Analysis 42
Cancer Statistics in the US 42
Cancer Incidence Statistics 42
Table 15: New Cancer Cases in the US by Affected Site: 2009 42
Table 16: New Cancer Cases in Males in US by Leading Site:
2009 (includes corresponding Graph/Chart) 44
Table 17: New Cancer Cases in Females in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 45
Cancer Mortality Statistics 45
Table 18: Cancer Related Deaths in the US by Affected Site:
2009 45
Table 19: Cancer Related Deaths in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 47
Table 20: Cancer Related Deaths in Females in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 47
Kidney Cancer Incidence Rates and Mortality Statistics 48
Table 21: Kidney Cancer Incidence Rates by Race/Ethnicity
per 10,000 Men (includes corresponding Graph/Chart) 48
Table 22: Kidney Cancer Incidence Rates by Race/Ethnicity
Per 10,000 Women (includes corresponding Graph/Chart) 48
Table 23: Kidney Cancer Mortality Rates by Race/Ethnicity
per 10,000 Men (includes corresponding Graph/Chart) 49
Table 24: Kidney Cancer Mortality Rates by Race/Ethnicity
Per 10,000 Women (includes corresponding Graph/Chart) 49
NCI Funding for Kidney Cancer on the Rise 50
Table 25: NCI's Annual Funding on Kidney Cancer Research
for Years 2007, 2008 & 2009 (includes corresponding Graph/
Chart) 50
Table 26: Allocation of Funds by Scientific/ Research Area
(2009) (includes corresponding Graph/Chart) 50
Strategic Corporate Developments 51
Focus on Select Major Players 54
B.Market Analytics 56
Table 27: The US Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 56
Table 28: The US 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 56
13. CANADA 57
A.Market Analysis 57
Cancer Incidence and Mortality Statistics in Canada 57
Table 29: Estimated New Cancer Cases by Type/Site Among
Canadian Men (2010) (includes corresponding Graph/Chart) 57
Table 30: Estimated New Cancer Cases by Type/Site Among
Canadian Women (2010) (includes corresponding Graph/Chart) 58
Table 31: Estimated Cancer Deaths by Type/Site Among
Canadian Men (2010) (includes corresponding Graph/Chart) 58
Table 32: Estimated Cancer Deaths by Type/Site Among
Canadian Women (2010) (includes corresponding Graph/Chart) 58
B.Market Analytics 59
Table 33: Canadian Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 59
Table 34: Canadian 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 59
14. JAPAN 60
Market Analysis 60
Table 35: Japanese Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 60
Table 36: Japanese 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 60
15. EUROPE 61
A.Market Analysis 61
Cancer Statistics in Europe 61
Table 37: Cancer Incidence in Europe by Site (2009)
(includes corresponding Graph/Chart) 61
Strategic Corporate Developments 62
B.Market Analytics 63
Table 38: European Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets
Independently Analyzed by Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) 63
Table 39: European 10-Year Perspective for Renal Cell
Carcinoma Drugs by Geographic Region - Percentage Breakdown
of Dollar Sales for France, Germany, Italy, UK, and Rest of
Europe Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart) 64
Table 40: European Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 65
Table 41: European 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 65
15a. FRANCE 66
Market Analysis 66
Table 42: French Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 66
Table 43: French 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 66
15b. GERMANY 67
A.Market Analysis 67
Strategic Corporate Development 67
Focus on Select Major Players 67
B.Market Analytics 69
Table 44: German Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 69
Table 45: German 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 69
15c. ITALY 70
Market Analysis 70
Table 46: Italian Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 70
Table 47: Italian 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 70
15d. THE UNITED KINGDOM 71
A.Market Analysis 71
Kidney Cancer Statistics 71
Strategic Corporate Developments 71
Focus on Select Major Players 72
B.Market Analytics 73
Table 48: The UK Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 73
Table 49: The UK 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 74
15e. REST OF EUROPE 75
A.Market Analysis 75
Focus on Select Major Players 75
B.Market Analytics 76
Table 50: Rest of European Recent Past, Current & Future
Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class -
Multikinase Inhibitors and Others Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 76
Table 51: Rest of European 10-Year Perspective for Renal
Cell Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 77
16. ASIA-PACIFIC 78
A.Market Analysis 78
Cancer Statistics in Asia-Pacific 78
Table 52: Cancer Incidence in Asia-Oceania by Site: 2009
(includes corresponding Graph/Chart) 78
Product Launch 79
B.Market Analytics 79
Table 53: Asia-Pacific Recent Past, Current & Future
Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class -
Multikinase Inhibitors and Others Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 79
Table 54: Asia-Pacific 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 80
17. REST OF WORLD 81
Market Analysis 81
Table 55: Rest of World Recent Past, Current & Future
Analysis for Renal Cell Carcinoma Drugs by Drug Class -
Multikinase Inhibitors and Others Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 81
Table 56: Rest of World 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 81
COMPETITIVE LANDSCAPE
Total Companies Profiled: 19 (including Divisions/Subsidiaries - 20)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 10
Canada 1
Europe 8
Germany 2
The United Kingdom 3
Rest of Europe 3
Asia-Pacific (Excluding Japan) 1
------------------------------------------
To order this report:
Drug and Medication Industry: Global Kidney Cancer Drugs Industry
Drug and Medication Business News
Check our Industry Analysis and Insights
Contact:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article